Panaxium

Executive Summary

Panaxium is a Paris-based bioelectronic medicine company founded in 2017, dedicated to developing a precision brain-machine interface (BMI) platform to treat brain injuries such as stroke and traumatic brain injury (TBI). The company's innovative approach combines an 'iontronic' neural interface with proprietary MRI and AI analysis to create personalized functional recovery therapies, aiming to prevent permanent disability. Currently in the pre-clinical stage, Panaxium has not disclosed total funding or valuation, but its proprietary technology addresses a significant unmet need in neurorehabilitation, where current treatments are limited. The platform's ability to precisely map and modulate neural circuits could position it as a breakthrough in neuromodulation, though it faces typical early-stage risks including technical validation, regulatory hurdles, and capital requirements. As a private French company with no disclosed revenue or partnerships, Panaxium's potential hinges on successful preclinical data and subsequent funding to advance toward first-in-human studies.

Upcoming Catalysts (preview)

• Q4 2026Publication of preclinical efficacy data in animal models of stroke/TBI60% success
• H1 2027Series A financing round to support IND-enabling studies50% success
• Q2 2027Grant of breakthrough device designation from FDA or equivalent European authority40% success